Olopatadine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Olopatadine: From Allergic Conjunctivitis to Rosacea Conjunctivitis
One-Sentence Summary
Olopatadine is an antihistamine/mast cell stabilizer with known clinical use in allergic conjunctivitis, though no formal indication record is available in this evidence pack. The TxGNN model predicts a possible association with Rosacea Conjunctivitis, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded (drug not marketed in the US/Taiwan); known clinical use is allergic conjunctivitis per mechanistic rationale |
| Predicted New Indication | Rosacea Conjunctivitis |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data is not available for olopatadine. Based on known information, olopatadine is an antihistamine/mast cell stabilizer class drug, with established clinical use in allergic conjunctivitis. Its efficacy in that setting is well documented in general clinical practice, though no formal Taiwan/US indication record exists in this evidence pack.
“Rosacea conjunctivitis” is not a standard, single clinical entity — it appears to be a knowledge-graph label that may correspond to ocular manifestations of rosacea (ocular rosacea), a condition with overlapping features to allergic/inflammatory conjunctivitis. The mechanistic link here is based purely on drug-disease embedding similarity within the TxGNN model, without corroborating MOA data or original-indication confirmation. Given the absence of both original indication data and MOA detail, the biological rationale for this specific prediction cannot be independently verified at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is evidence level L5 — supported only by the TxGNN model score, with zero clinical trials or literature backing it, and a Blocking-severity data gap on TFDA safety labeling. There is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA/FDA package insert data (warnings, contraindications) — currently a Blocking gap
- Confirmed original indication and MOA from DrugBank or regulatory source
- Clarification of “rosacea conjunctivitis” as a clinical entity (e.g., confirm whether it maps to ocular rosacea)
- Literature or preclinical evidence establishing a mechanistic link between olopatadine and rosacea-associated conjunctivitis
- At minimum, observational or case-level evidence before moving beyond S0/Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.